BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved ...

According to the Imvexxy prescribing information, women should generally be started at the 4mcg dosage strength with dosage adjustment guided by clinical response. Imvexxy (estradiol vaginal inserts) ...

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY ® in Canada ...

The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12. The Food and ...

Imvexxy (estradiol) is a prescription drug that’s used to treat moderate to severe painful sex from menopause. The drug comes as vaginal capsules you’ll insert vaginally. The maintenance dosage is ...

It's important for clinicians to ask women whether they are experiencing symptoms of genitourinary syndrome of menopause (GSM) before and after menopause, according to a new statement from the North ...

MONTREAL & BOCA RATON, Fla.--(BUSINESS WIRE)-- Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD ...

NEW YORK (Reuters Health) - An ultra-low dose of 10 micrograms of estradiol significantly improves vaginal tissue, pH balance, and urogenital symptoms in postmenopausal women with vaginal atrophy, new ...

TherapeuticsMD, Inc. TXMD, an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY (estradiol vaginal inserts) for the ...

The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12. The Food and ...